A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. [electronic resource]
Producer: 20210122Description: 888-894 p. digitalISSN:- 2374-2445
- Adult
- Aged
- Aged, 80 and over
- Alkaline Phosphatase -- metabolism
- Antineoplastic Agents, Immunological -- adverse effects
- B7-H1 Antigen -- antagonists & inhibitors
- Biliary Tract Neoplasms -- diagnostic imaging
- Biomarkers, Tumor -- antagonists & inhibitors
- Drug Resistance, Neoplasm
- Female
- Humans
- Hyponatremia -- chemically induced
- Immune Checkpoint Inhibitors -- adverse effects
- Male
- Middle Aged
- Nivolumab -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.